Flu and RSV Climb on Both Sides of the Atlantic as UK Hospitalizations Spike

CIDRAP reports that COVID-19 activity remains low in the United States and Europe, but influenza and RSV are climbing. In the US, flu is edging up in most areas while care-seeking for acute respiratory illness still stays low; RSV is increasing in the Southeast, South, and Mid-Atlantic, with rising emergency-department visits and hospitalizations among children ages 0–4. The CDC also notes elevated Mycoplasma pneumoniae (“walking pneumonia”) in some places and above-baseline pertussis. In Europe, flu activity began three to four weeks earlier than the previous two seasons, and primary-care respiratory visits are elevated in about half of reporting countries. The UK saw a major jump: 2,660 flu patients hospitalized daily last week, up 55% week over week, with officials warning there’s no peak in sight. (cidrap.umn.edu)

CRISPR’s Platform Moment: How “N-of-1” Gene Editing Could Scale to Rare Disease Medicine

CRISPR’s first big medical win targeted sickle-cell disease—one shared mutation, one pathway to an FDA-approved therapy. This Atlantic feature argues 2025 is when gene editing pushed into harder terrain: ultra-rare disorders where each patient can carry a unique mutation, and “one drug for many people” stops working. It centers on the case of baby KJ Muldoon, who received a customized CRISPR treatment tailored to his specific mutation—proof that bespoke editing can be designed quickly enough to matter clinically. The piece explains the emerging “platform” idea: reuse a validated delivery/editor template and swap guide RNAs to match each patient, cutting cost and timelines. A major bottleneck remains regulation—how to approve therapies that may exist for a single child. (The Atlantic)

FDA Clears First Gene Therapy for Wiskott–Aldrich Syndrome

The FDA has approved Waskyra, the first gene therapy for Wiskott–Aldrich syndrome (WAS), a rare, life-threatening immune disorder. Reuters notes that WAS weakens immune defenses and is associated with frequent infections alongside bleeding and bruising problems, plus eczema-like skin issues—symptoms that can be severe and hard to manage with conventional care. The approval is notable because it expands the set of inherited immunologic diseases now treatable with one-time genetic interventions rather than lifelong supportive therapy. While Reuters’ report is brief, the regulatory milestone signals continued momentum for gene-therapy platforms in ultra-rare indications, where patient numbers are small but unmet need is high. Expect attention next on access and durability—how broadly patients can receive treatment and how long the benefit persists. (Reuters)

BioCryst’s Hereditary Angioedema Drug Gets Kid-Friendly “Pellet” Formulation

BioCryst’s Orladeyo, a once-daily oral preventive for hereditary angioedema (HAE), is now cleared in an oral pellet formulation for children aged two to under 12, Reuters reports. Orladeyo was originally approved in late 2020 as a capsule for patients 12 and older; the new formulation targets a practical barrier in pediatric rare-disease care: swallowing capsules and keeping dosing consistent. HAE attacks can involve severe swelling and can be dangerous depending on the site of swelling, so prevention and adherence matter. The approval widens the eligible population and may help families maintain prophylaxis with fewer administration hurdles. For biotech watchers, it’s a reminder that “innovation” isn’t only new molecules—delivery and formulation can unlock real-world uptake, especially in pediatrics where the same active drug may need a different physical product to be usable. (Reuters)

Base-Edited “Off-the-Shelf” CAR T Reaches Adults With Hard-to-Treat T-ALL

King’s College Hospital reports it has treated the first adult patients with a new gene therapy, BE-CAR7, for an aggressive blood cancer—T-cell acute lymphoblastic leukaemia (T-ALL). The approach uses base editing, a CRISPR-derived method that changes single DNA letters without cutting the double helix, aiming to reduce chromosomal damage risk. The hospital describes BE-CAR7 as “universal” CAR T: donor T cells are engineered in a clean-room process using custom RNA/mRNA and a lentiviral vector, then banked for use. Once infused, the edited CAR T cells can rapidly eliminate T cells, including leukemic cells; if leukemia is cleared within about four weeks, patients’ immunity is rebuilt via bone marrow transplant over months. Trial results were published in NEJM and presented at ASH, per the hospital. (King’s College Hospital)

UCL: BE-CAR7 Trial Reports Deep Remissions in T-ALL Using Base-Edited Cells

UCL highlights clinical-trial results for BE-CAR7, a base-edited CAR T therapy targeting T-cell acute lymphoblastic leukaemia (T-ALL), describing it as the first in-human application of base-edited cells. The university says Alyssa Tapley received the first treatment in 2022 at age 13 after other options were exhausted, and the trial has since expanded to additional patients. Results published in The New England Journal of Medicine include: 82% of patients achieving very deep remissions that enabled them to proceed to stem cell transplant, and 64% remaining disease-free, with earliest recipients now three years out and off treatment. UCL notes side effects such as low blood counts, cytokine release syndrome, and rashes were “tolerable,” while viral infections were a key risk until immunity recovered. It’s an important signal that precision editing can support scalable, donor-derived cellular medicines. (University College London)

---

---

Nature Biotechnology: FDA Approves Arrowhead’s siRNA for Familial Chylomicronemia Syndrome

Nature Biotechnology reports the FDA has approved Arrowhead Pharmaceuticals’ Redemplo (plozasiran) for familial chylomicronemia syndrome, a rare genetic disorder in which patients can’t properly clear triglyceride-rich chylomicrons, driving extremely high triglycerides and raising pancreatitis risk. Redemplo is a GalNAc-conjugated small interfering RNA (siRNA) that targets APOC3 (apolipoprotein C-III), a liver-made glycoprotein associated with chylomicrons that inhibits triglyceride breakdown. By reducing APOC3 production, the therapy improves chylomicron clearance and helps restore triglycerides to safer levels. The item is short, but the significance is large: it’s another validation of liver-targeted RNAi as a drug platform, pairing modern conjugate chemistry with gene-silencing mechanisms to address inherited metabolic risk where traditional small molecules often struggle. (Nature)

Nature Biotechnology: A Recombinant “Broad-Spectrum” Antivenom Built From Nanobodies

A Nature Biotechnology research highlight summarizes work aiming to solve a painful limitation of traditional antivenoms: they’re often species-specific and may not prevent tissue damage. The report describes a strategy that immunized an alpaca and a llama with venoms from 18 snake species, then used phage display to identify nanobodies—small antibody fragments—with broad neutralization against key toxin families (including three-finger toxins and phospholipase A₂). Eight top nanobodies were combined into a recombinant antivenom cocktail. In mouse testing, pre-incubation experiments found the cocktail protected against death for 17 of 18 venoms tested; in a “rescue” scenario meant to mimic real bites, the recombinant mix outperformed a commercial antivenom and reduced venom-induced skin lesion size. If this generalizes, it points toward more standardized, scalable antivenoms with wider coverage. (Nature)

Synthetic Biology’s “What Went Wrong” Playbook: How to Build a Eukaryotic Genome

EurekAlert summarizes a Nature Biotechnology paper distilling lessons from the Synthetic Yeast Genome Project (Sc2.0), a decade-long international effort to redesign and chemically synthesize all 16 chromosomes of baker’s yeast. The release frames the work as a troubleshooting manual: not just the successes, but the failures and fixes that emerged while rewriting a eukaryotic genome “from the ground up.” It describes core design moves used repeatedly across chromosomes—removing unstable genetic elements, adding molecular “watermarks” to distinguish synthetic DNA, and integrating SCRaMbLE, a gene-shuffling system that lets researchers rearrange genes to probe function. The broader pitch is acceleration: codifying pitfalls and best practices could shorten timelines for future engineered organisms, from climate-resilient crops to cell factories that produce medicines, materials, or fuels. (EurekAlert!)

Mutant Yeast That Thrives in Its Own Product Could Boost Bio-Based Chemical Manufacturing

This EurekAlert release spotlights efforts to make yeast-based production of 2,3-butanediol (2,3-BDO) commercially viable. 2,3-BDO is used across industries including pharmaceuticals and cosmetics, but Saccharomyces cerevisiae struggles when concentrations get high—its growth and output drop, bottlenecking scale-up. Researchers at Osaka Metropolitan University introduced mutations across genomic DNA and then stress-tested engineered strains under ethanol, heat, and low pH. They report selecting a mutant strain (YPH499/Co58) that proliferated 122 times more than the parent strain in high-concentration 2,3-BDO conditions. Gene-expression analysis implicated pathways tied to proteasomes, peroxisomes, the TCA cycle, mitochondria, and transcriptional regulation in tolerance. The practical takeaway: generalizable mutation-and-selection methods can yield “tough” microbes that keep producing even in harsh, product-rich fermentation tanks.(EurekAlert!)

350-Nanometer “THIN” Bioelectronics Self-Adheres to Wet Tissue—No Sutures, No Glue

Researchers described in Phys.org report a bioelectronics material called THIN (transformable and imperceptible hydrogel-elastomer ionic-electronic nanomembrane) designed to interface with living tissue without the usual tradeoffs: adhesives, bulky packaging, or mechanical supports that can irritate moving organs. The membrane is about 350 nanometers thick and starts as a dry, rigid film; once hydrated by bodily fluids it becomes ultra-soft and tissue-like. The team shows THIN can self-adhere to wet tissue (even highly curved, microstructured surfaces) via hydration-triggered swelling and mussel-inspired interfacial chemistry, maintaining contact under dynamic motion such as the beating heart. Implemented as an organic electrochemical transistor, the device can amplify subtle biosignals for in vivo monitoring. The study is reported as published in Nature Nanotechnology, pointing to near-term medical sensing applications. (Phys.org)

China Logs Three Orbital Long March Launches in One Day, Expanding Broadband and Tech-Demo Satellites

SpaceDaily reports China achieved three Long March rocket launches in a single day, a new marker of cadence for its space program. The first, a Long March 6A from Taiyuan, deployed internet satellites to expand a state-managed broadband constellation that already had more than 110 spacecraft on orbit. The second, a Long March 4B from Jiuquan, carried Yaogan 47, described as supporting land resource surveys, urban mapping, agricultural yield monitoring, and environmental/disaster applications. The third, a Long March 3B from Xichang, placed Communication Technology Demonstrator 22 into orbit to provide relay services, broadcast distribution, and in-orbit technology demonstrations. Beyond the headline, the story is about operational tempo: frequent, diversified launches are a capability in themselves, enabling faster iteration in constellations and space-based infrastructure. (spacedaily.com)

Record-Breaking Species Discovery: Why New Life Is Being Named Faster Than Ever

A new Science Advances analysis, discussed on NPR, tracks how quickly scientists have been describing Earth’s species since Carl Linnaeus began modern taxonomy in the 1750s. Coauthor John Wiens (University of Arizona) finds discovery rose slowly for centuries, peaked around 1900, then crashed during World War I and again during World War II before climbing steadily. Today, species description rates are at their highest on record—about 17,000 described species per year—yet only 2.5 million species are formally known. Estimates for total species richness range from the low millions to the low trillions, with microbes driving much of the uncertainty; Wiens’ best guess is hundreds of millions to low billions. Knowing what exists can aid conservation and fuel medical surprises, as with Ozempic’s Gila monster inspiration. (wwno.org)

---

---

---